Key Financial Figures

Standalone Results (Q2 FY2026):

  • Net Sales/Income from operations: ₹4,652.70 lakh
  • Other Income: (₹0.46) lakh
  • Total Revenue: ₹4,652.23 lakh
  • Total Expenses: ₹4,317.15 lakh
  • Profit before tax: ₹335.08 lakh
  • Total Tax Expense: ₹100.19 lakh
  • Net Profit: ₹234.89 lakh
  • Basic EPS: ₹1.73
  • Diluted EPS: ₹1.73

Consolidated Results (Q2 FY2026):

  • Net Sales/Income from operations: ₹5,483.39 lakh
  • Other Income: (₹0.46) lakh
  • Total Revenue: ₹5,482.93 lakh
  • Total Expenses: ₹4,970.92 lakh
  • Profit before tax: ₹512.01 lakh
  • Total Tax Expense: ₹100.14 lakh
  • Net Profit: ₹411.87 lakh
  • Attributable to controlling interest: ₹341.08 lakh
  • Attributable to non-controlling interest: ₹70.79 lakh
  • Basic EPS: ₹3.04
  • Diluted EPS: ₹3.04

Half Year Performance (H1 FY2026):

Standalone:

  • Net Profit: ₹487.58 lakh
  • Basic EPS: ₹3.59

Consolidated:

  • Net Profit: ₹596.47 lakh
  • Basic EPS: ₹4.40

Regulatory Compliance Matter

The Board took note of notices received from BSE Limited and National Stock Exchange of India Limited dated August 25, 2026, regarding fines imposed for non-compliance with SEBI (LODR) Regulations, 2015, specifically Regulation 19(1)/19(2) relating to the composition of the Nomination and Remuneration Committee for the quarter ended June 30, 2026.

Each exchange levied a fine of ₹34,000 plus GST of ₹6,120, aggregating to ₹40,120 per exchange, totaling ₹80,240 for both exchanges.

The Board was informed about corrective measures undertaken by the Company to ensure compliance with regulatory requirements and avoid recurrence.

Assets and Liabilities Position (as of September 30, 2026)

Standalone:

  • Total Assets: ₹36,151.83 lakh
  • Total Equity: ₹28,460.47 lakh
  • Equity Share Capital: ₹1,356.28 lakh
  • Non-current Liabilities: ₹390.03 lakh
  • Current Liabilities: ₹7,301.33 lakh

Consolidated:

  • Total Assets: ₹37,198.84 lakh
  • Total Equity: ₹28,151.47 lakh
  • Equity Share Capital: ₹1,356.28 lakh
  • Non-current Liabilities: ₹1,024.69 lakh
  • Current Liabilities: ₹8,022.68 lakh

Cash Flow Statements (H1 FY2026)

Standalone:

  • Net cash from operating activities: ₹1,467.62 lakh
  • Net cash used in investing activities: (₹34.06) lakh
  • Net cash used in financing activities: (₹1,082.87) lakh
  • Net increase in cash: ₹350.69 lakh

Consolidated:

  • Net cash from operating activities: ₹1,355.48 lakh
  • Net cash used in investing activities: (₹42.00) lakh
  • Net cash used in financing activities: (₹960.72) lakh
  • Net increase in cash: ₹352.76 lakh

Auditor Review

Both standalone and consolidated financial results were reviewed by Rai Qimat & Associates, Chartered Accountants, who issued unmodified review reports dated November 13, 2026.

The consolidated review report notes that subsidiaries Opal Pharmaceuticals Pty Ltd (wholly owned) and Medicamen Life Sciences Private Limited contributed total revenues of ₹5,482.93 lakh and net profit of ₹411.87 lakh for the quarter.

Additional Information

  • The company operates in a single segment: Pharmaceutical
  • Paid-up equity share capital: ₹1,356.28 lakh (₹10 per share)
  • Financial results prepared in accordance with Indian Accounting Standards (Ind AS)
  • Results available on company website: www.medicamen.com